Jose Lutzky, M.D., an oncologist at Sylvester, is leading efforts in the use of tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma.
Recently FDA-approved, this cellular therapy harnesses a patient's own immune cells to fight cancer.
Dr. Lutzky emphasized the significant advancement TIL therapy represents, particularly for patients whose melanoma has failed previous treatments. Sylvester is the only South Florida center offering this therapy.
Dr. Lutzky is also involved in a clinical trial testing modified TIL therapy to remove the PD-1 gene, aiming to boost immune cell activity and improve treatment efficacy.